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AbstrAct
Introduction Acute gout occurs in people with chronic 
kidney disease, who are commonly older people with 
comorbidities such as hypertension, heart disease and 
diabetes. Potentially harmful treatments are administered 
to these vulnerable patients due to a lack of clear 
evidence. Newly available treatment that targets a key 
inflammatory pathway in acute gout attacks provides an 
opportunity to undertake the first-ever trial specifically 
looking treating people with kidney disease. This paper 
describes the protocol for a feasibility randomised 
controlled trial (RCT) comparing anakinra, a novel 
interleukin-1 antagonist versus steroids in people with 
chronic kidney disease (ASGARD). 
Methods and analysis ASGARD is a two-parallel 
group double-blind, double-dummy multicentre RCT 
comparing anakinra 100 mg, an interleukin-1 antagonist, 
subcutaneous for 5 days against intramuscular 
methylprednisolone 120 mg. The primary objective is to 
assess the feasibility of the trial design and procedures for 
a definitive RCT. The specific aims are: (1) test recruitment 
and retention rates and willingness to be randomised; (2) 
test eligibility criteria; (3) collect and analyse outcome 
data to inform sample and power calculations for a trial 
of efficacy; (4) collect economic data to inform a future 
economic evaluation estimating costs of treatment and 
(5) assess capacity of the project to scale up to a national 
multicentre trial. We will also gather qualitative insights 
from participants. It aims to recruit 32 patients with a 
1:1 randomisation. Information from this feasibility study 
will help design a definitive trial and provide general 
information in designing acute gout studies. 
Ethics and dissemination The London-Central Ethics 
Committee approved the protocol. The results will be 
disseminated in peer-reviewed journals and at scientific 
conferences.
trial registration number EudraCT No. 2015-001787-
19, NCT/ Clinicalstrials. gov No. NCT02578394, pre-results, 
WHO Universal Trials Reference No. U1111-1175-1977. 
NIHR Grant PB-PG-0614–34090.
IntroductIon
Background and rationale
Chronic kidney disease (CKD) affects 5% of 
the UK population1 and 40% of patients with 
CKD 3 and 4 have chronic gout,2 suggesting 
that 1.32 million people, predominantly 
older patients, have CKD and gout in the UK. 
The overall incidence of acute gout attacks 
has been estimated to be approximately 2 per 
1000 person-years.3 4 The prevalence of gout 
is increasing due to increasing prevalence of 
comorbid conditions that are associated with 
hyperuricaemia such as hypertension, obesity, 
metabolic syndrome, diabetes and chronic 
kidney disease.4 5
In a UK study, approximately 89.4% of 
patients were treated for their acute attack 
with non-steroidal anti-inflammatory agents 
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Protocol
strengths and limitations of this study
 ► Assessing the feasibility of undertaking a definitive 
robustly designed double-blind, double-dummy 
study.
 ► Qualitative aspects to current study design will help 
future study be more patient orientated.
 ► Current study is not designed to find differences in 
outcomes.
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(NSAIDS) which are well known to worsen kidney failure.5 
Secondary care data from the USA showed that up to 
50% of acute gout patients had CKD and 40% were given 
contraindicated medications.6 This is similar to our expe-
rience where a review of inpatient acute gout care showed 
half of all patients with acute gout and kidney disease 
were given potentially harmful medications. Mismanage-
ment of acute gout attacks in patient with kidney disease 
occurs as there is no firm evidence base for treating acute 
gout attacks in people with kidney disease.7
The lack of evidence in the literature for the use of 
conventional agents in patients with CKD is primarily 
because patients with CKD are excluded as NSAIDS are 
used as an active comparator in randomised controlled 
trials (RCTs). Guidelines continue to suggest using 
colchicine with in patients with renal disease even with its 
toxicity profile and poor evidence base.8–10 We now have 
an opportunity to conduct a trial using two agents that 
would not be expected to have adverse effects on renal 
function.
treatment options for patient with acute gout attacks and cKd
NSAIDS have the largest evidence base for use in acute 
gout but are contraindicated in CKD as they can cause 
an acute kidney injury. They can also worsen heart 
failure, hypertension, liver failure and cause gastroin-
testinal bleeding.7 11 Colchicine is an alternative anti-in-
flammatory agent, it has a narrow therapeutic index 
and a low-dose regime is advocated following findings 
in the high versus low dosing of oral colchicine for early 
acute gout flare (AGREE) trial. Even though this study 
excluded patients with moderate to severe kidney disease 
(glomerular filtration rate (GFR) <60 mL/m3), 23% of 
patients on the low-dose treatment still experienced 
diarrhoea.12 Diarrhoea is more common in patients with 
CKD, they are also more likely to have drug accumulation 
and serious side effects from toxicity such as bone marrow 
failure, rhabdomyolysis, pancreatitis and myopathy.7
Glucocorticoids are an effective treatment with some 
evidence for use in patients with CKD from older trials. 
Triamcinolone, a long-acting synthetic corticosteroid, 
was shown to be as effective as adrenocorticotrophic 
hormone, a hormone that increases endogenous cortisol 
secretion.11 A more recent double-blind randomised 
controlled study13 showed that prednisolone 35 mg for 5 
days was not inferior to naproxen for acute gout attacks, 
although patients with moderate to severe renal impair-
ment were excluded.
Interleukin-1 inhibitors
Interleukin-1 (IL-1) signalling has been shown to play a 
key role in gout-associated inflammation14 15 and targeted 
therapy is now available. Two agents of IL-1 have been 
used in RCTs. Rilonocept, an IL-1 decoy receptor, has 
been shown to be efficacious in reducing acute flares 
during the initiation of urate lowering therapy,16 17 but 
no added benefit was obtained for the treatment of 
acute gout when it was used in addition to an NSAID.18 
Canakinumab, a monoclonal antibody against IL-1 beta, 
showed efficacy preventing acute flares during the initi-
ation of urate-lowering therapy19 and for acute gout in 
patients with difficult disease or contraindication to 
colchicine or NSAIDs.20–22 It was associated with increased 
adverse events after a single injection23 which was felt in 
part due to its prolonged action which can be for many 
weeks.24 This study will use anakinra (Kineret), an IL-1 
receptor antagonist that competes with IL-1beta for its 
receptor. A pilot study of its use in gout showed prompt 
resolution of symptoms in patients treated with anak-
inra,25 including in three patients with renal impairment. 
There have been further reports of the use of anakinra 
in difficult to treat cases showing good efficacy, with most 
patients having a good response within 24 hours.26–31
Anakinra has a good pharmacokinetic profile with a 
shorter duration of action, accumulation can occur in 
severe renal failure,32 and this had been linked to an 
increased risk of infection in one case report.31 The dose 
of a daily 100 mg has been used in studies looking at treat-
ment of rheumatoid arthritis (usually between 50 and 
150 mg), and it was well tolerated for up to 3 years.33–37 
The licensed use of anakinra is for Cryopryin Associated 
Periodic Syndrome where dosing is 3–4 mg/kg in severe 
disease (doses up to 800 mg).38 The rationale for the 
duration of treatment use of 100 mg subcutaneous for 5 
days come from emerging data where anakinra has been 
used to treat acute gout with good efficacy and in patients 
with CKD without too many adverse events.25–29 Some 
reports vary between 3 to 5 days but most use 5 days’ 
duration of treatment to ensure adequate response in all 
patients, including our own experience.30 We have inten-
tionally avoided using anakinra in patients with severe 
renal failure (GFR <30 mL/min/1.73 m2) although it 
has been used safely in patient on haemodialysis using 
an alternate regime,39 and we have some experience of 
this in our centre.30 Anakinra is much cheaper compared 
with canakinumab (£131.15 versus £9927.90 for a course 
of treatment), which has been given a license in the UK 
for use in difficult to treat gout.
Safety experience stem mainly from studies in rheuma-
toid arthritis where patients were on concurrent immu-
nosuppressive treatment and the duration of treatment 
was prolonged (up to 6 months). A slightly higher risk of 
infection (2%) and neutropaenia was noted. We do not 
anticipate these issues as the treatment time for acute 
gout will be short, 5 days versus many months, and we 
feel the risk of infection should be much less. We are 
excluding people with concurrent immunosuppressive 
treatment and will exclude people with serious infection. 
There are some data of the use of anakinra in the setting 
of an active infection from the first clinical trial where 
it was used to treat people with severe septicaemia and 
those who received anakinra were not worse off.40 There 
are also reports of the use of anakinra for acute gout for 
hospitalised inpatients with active infections and multiple 
comorbidities.27–29 There was one case report of neutro-
paenia in one patient with a kidney transplant with severe 
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Figure 1 ASGARD study flowchart. Randomised participants will receive allocated treatment and placebo equivalent. ACR, 
albumin creatinine ratio; ASGARD, interleukin-1 antagonist versus steroids in people with chronic kidney disease; CKD, chronic 
kidney disease; EQ-5D-5L, Five-level EuroQol five-dimensional questionnaire HAQ-DI, Health assessment questionnaire 
disability index; LEFS, Lower Extremity Functional Scale; QoL, quality of life; SF-36, 36-Item Short Form Survey; VAS, Visual 
Analogue Scale.
renal impairment.31 Blood counts will be checked at the 
end of treatment at day 5 and participants will also be 
assessed for infection face to face on day 2, day 7 and 8 
weeks, and by telephone contact on day 3, day 4 and day 
5. Participants will be asked to stop treatment if serious 
infection develops.
Methylprednisolone
Methylprednisolone acetate is one of the most commonly 
used long-acting intramuscular agent in the UK, we have 
shown this in our region,41 and it is equivalent to Triam-
cinolone in other joint conditions.42
We are using methylprednisolone 120 mg given by intra-
muscular injection which is as efficacious as oral steroids 
with a lower cumulative dose (120 mg vs 175 mg) in other 
rheumatology conditions, and this is equivalent to the 
dose of oral prednisolone used in the trial by Janssens et 
al13 (35 mg for 5 days). This well-designed double-blind 
randomised controlled study showed that prednisolone 
35 mg for 5 days was not inferior to naproxen. The rate 
group.bmj.com on September 13, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
4 Balasubramaniam G, et al. BMJ Open 2017;7:e017121. doi:10.1136/bmjopen-2017-017121
Open Access 
box 1 Anakinra versus steroids for gout attacks in 
patients with chronic renal disease inclusion criteria
Patients who meet inclusion criteria will be approached by a study 
investigator. Consent for participation will be sought. On gaining 
consent, the investigator will go through exclusion criteria.
1. Subjects capable of giving informed consent;
2. Male or non-pregnant, non-nursing female;
3. ≥18 years of age;
4. Estimated glomerular filtration rate <60 mL/min/1.73 m2 and ≥30 
mL/min/1.73 m2 as calculated using serum creatinine and modified 
Modification of Diet in Renal Disease Study formula or Chronic 
Kidney Disease Epidemiology Collaboration on two occasions at 
least 2 months apart with one being in the last 6 months. Creatinine 
at time of presentation can be used unless participant has an acute 
kidney injury as defined by serum creatinine rise by ≥26 µmol/L 
within 48 hours or ≥1.5-fold rise from baseline value.
5. Diagnosis of acute gout arthritis as defined by the American 
College of Rheumatology 1977 preliminary criteria;
6. Gout attack less ≤36 hours;
7. Baseline pain intensity greater than or equal to 50 mm on the 
0–100 mm Visual Analogue Scale. In the case of multiple joints 
(≤3), the most affected joint will be assessed.
of side effects even with short-term steroid treatment in 
acute gout is unknown. Our study may help establish 
steroids, especially intramuscular methylprednisolone 
which has limited evidence base, as a potential safe, cheap 
and readily available treatment for acute gout in patients 
with renal disease. If the initial results show equivalent 
efficacy between the two treatment arms, then we could 
go on to establish steroids as the standard treatment and 
make considerable savings.
Our use is only as a one-off injection (as is commonly 
done in routine practice), and we do not anticipate 
long-term complications. Short term side-effects we may 
encounter are uncontrolled blood sugars in people with 
diabetes and worsening oedema in people with heart 
failure and kidney failure. The latter should occur less 
with methylprednisolone which is associated with less 
mineralocorticoid effect than other steroids (eg, pred-
nisolone). The placebo equivalent for the methylpred-
nisolone will be Lipofundin, a lipid emulsion commonly 
used in parenteral nutrition but has been use as a placebo 
agent in other trial using steroids.
objectives
Primary objective
The primary objective of interleukin-1 antagonist versus 
steroids in people with chronic kidney disease (ASGARD) 
is to assess the feasibility of the trial design and proce-
dures for a definitive RCT. The specific aims are: (1) test 
recruitment and retention rates and willingness to be 
randomised; (2) test eligibility criteria; (3) collect and 
analyse outcome data to inform sample and power calcu-
lations for a trial of efficacy; (4) collect economic data to 
inform a future economic evaluation estimating costs of 
treatment and (5) assess capacity of the project to scale 
up to a national multicentre trial. We will also gather 
qualitative insights from participants about their experi-
ence from being in the feasibility trial to help design the 
subsequent definitive trial.
Secondary objectives
Information will be obtained to help with the design 
of the subsequent study including testing of proposed 
primary and secondary outcomes described below.
trial design
ASGARD is a two-parallel group double-blind, double 
dummy multicentre RCT with a 1:1 allocation ratio 
comparing anakinra 100 mg subcutaneous for 5 days with 
a one-off methylprednisolone (Depo-Medrone) 120 mg 
intramuscular injection (figure 1) (see online supple-
mentary material).
MEthods
Study setting
ASGARD aims to recruit from centres in the East of England 
region. Recruitment will be from patients who present to 
primary and secondary care with acute gout and chronic 
kidney disease, this will also include inpatients who develop 
an acute gout attack. Known patients with moderate kidney 
disease will also be primed to contact the research team by 
working with local primary care providers to send out letters 
of invitation. Recruitment will occur in the secondary care 
setting with treatment occurring on an outpatient basis or 
can occur in secondary care if symptoms warrant admission 
or if the participant is already an inpatient and develops an 
acute gout attack.
Eligibility criteria
baseline assessments
Baseline assessment will include basic medical observations, 
routine bloods and basic clinical examination (boxes 1 and 
2). The 2015 American College of Rheumatology/Euro-
pean League Against Rheumatism Collaborative Initiative 
will also be used at baseline assessment.43
Interventions
Eligible participants will undergo 1:1 block randomisation 
to one of two treatment arms; anakinra 100 mg s/c daily 
for 5 days and one-off placebo methylprednisolone (Lipo-
fundin MCT) intramuscular (gluteal) or one-off intramus-
cular methylprednisolone (Depo-Medrone) and placebo 
anakinra subcutaneous for 5 days. The study drug and 
its placebo will be provided by SOBI. Lipofundin will be 
purchased by the coordinating centre pharmacy by the 
usual route.
For anakinra and its equivalent placebo, participants 
will be issued a pharmacy box with individual syringes 
in syringe holders and a sharps bin. Each syringe will be 
labelled day 1 (already administered) up to day 5. Day 1 
treatment will be administered after baseline assessment 
and investigations.
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box 2 Anakinra versus steroids for gout attacks in patients with chronic renal disease inclusion criteria exclusion criteria
1. Treatment with colchicine in the last week;
2. Initiation of or change to dose of non-steroidal anti-inflammatory drugs (NSAIDs) in the last week. NSAID use is not an exclusion criteria if taken at 
a stable dose for at least 4 weeks;
3. Initiation of or change to dose of systemic steroids in the last week. Systemic steroid use is no an exclusion criteria if taken at an equivalent dose 
of 10 mg prednisolone or less for the last 4 weeks;
4. Polyarticular gout, that is, affecting four or more four joints;
5. Rheumatoid arthritis, evidence/suspicion of infectious/septic arthritis or other acute inflammatory arthritis such as systemic lupus erythematosus, 
mixed connective tissue disease, scleroderma, polymyositis or significant systemic involvement secondary to rheumatoid arthritis.
6. Concurrent immunosuppression/immunomodulatory treatment (calcineurin inhibitor, antiproliferative or biological) therapy for other reason, that is, 
organ transplant;
7. History or current inflammatory joint disease other than gout (eg, rheumatoid arthritis, reactive arthritis, psoriatic arthritis, seronegative 
spondyloarthropathy, Lyme disease);
8. Current active malignancy (with the exception of basal cell or squamous cell carcinoma of the skin, cervical intraepithelial neoplasia and non-
metastatic/advanced prostate cancer);
9. Any patients with contraindication to intramuscular injection such as coagulopathy or thrombocytopaenia (platelet count <100×109/L (100,000/
mm3));
10. Abnormal liver function tests: total bilirubin >upper limit of normal, alanine aminotransferase or aspartate aminotransferase >2 times upper limit 
of normal;
11. Haemoglobin<85 g/L (8.5 g/dL);
12. White blood cell count <1.5×109/L (1000/mm3), absolute neutrophil count <1.5×109/L (1000/mm3);
13. Evidence of serious active infection requiring intravenous antibiotic drug administration within last 4 weeks. Potential participants who were 
empirically treated with a course of intravenous antibiotics for a presumptive diagnosis of an infection may be eligible where the treating medical 
team has subsequently excluded an active infection and consequently discontinued antibiotic therapy at least 4 hours before randomisation. These 
potential participants can be discussed with the investigator where clarity is required;
14. Evidence of uncontrolled concomitant cardiovascular, nervous system, pulmonary (including obstructive pulmonary disease), hepatic, endocrine 
(including uncontrolled diabetes) or gastrointestinal disease. Potential participants who have active concomitant disease can only be eligible after 
discussion and agreement with the treating medical team;
15. Known positive hepatitis B virus surface antigen, hepatitis C antibody or HIV.
16. Females of childbearing potential who are not willing to use highly effective birth control methods from the time of consent to 1 week after 
treatment discontinuation. Highly effective method of contraception (hormonal or barrier method of birth control, abstinence) consist of:
17. Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation; oral, intravaginal, transdermal;
18. Progestogen-only hormonal contraception associated with inhibition of ovulation; oral, injectable, implantable;
19. Intrauterine device or intrauterine hormone-releasing system;
20. Bilateral tubal occlusion or vasectomised partner;
21. Sexual abstinence, defined as true abstinence when it is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (eg, 
calendar, ovulation, sympthothermal, postovulation) and withdrawal methods are not acceptable methods of contraception;
22. Men who are sexually active with a female partner who are not willing to use highly effective birth control methods from the time of consent to 
1 week after treatment discontinuation;
23. Females of childbearing potential must have a negative pregnancy test (highly sensitive urine or serum pregnancy test after a confirmed 
menstrual period) within 7 days prior to treatment initiation. Subjects are considered not of childbearing potential if they are surgically sterile (ie, 
they have undergone a hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or they are postmenopausal.
24. Females must not be breastfeeding;
25. Patients who have had treatment as part of this trial cannot have repeat treatment for another flare as part of the trial;
26. Patients with allergies to excipients of IMPs: citric acid, anhydrous, sodium chloride, disodium edetate dehydrate, polysorbate 80, sodium 
hydroxide. Hypersensitivity to Escherichia coli-derived proteins, egg proteins and soy proteins. Patients with a latex allergy are also not eligible as 
the inner needle cover of the prefilled syringe contains dry natural rubber (a derivative of latex).
The participant will be taught to self-administer the 
subcutaneous injection. Participant will then attend on 
day 2 for assessment of self-injection and subsequently 
will undertake self-injection themselves on days 3, 4 
and 5. Participants unable to self-inject will receive 
their injections from a carer, family member or district 
nurse.
Intramuscular methylprednisolone or Lipofundin 
syringes will be prepared by a member of the research 
team not involved with the trial assessments (ie, unblinded 
research nurse).
Modifications
Injection sites will be assessed visually on day 2 and day 7 
(figure 2), and by telephone contact from day 3 to day 6. 
Blood tests will be taken on day 2 and day 7 to check for 
neutropaenia and any signs of infection. Treatment will be 
stopped in the event of any adverse reaction during subcu-
taneous injections, oral prednisolone 35 mg orally for 5 days 
will be used as rescue treatment if symptoms of acute attack 
persist. Side effects to methylprednisolone such as wors-
ening oedema and uncontrolled diabetes (if diabetic) will 
be monitored and reported as adverse events.
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Figure 2 Anakinra versus steroids for gout attacks in patients with chronic renal disease participant timeline. Participants will 
be assessed by research team at day 1 (randomisation), day 2, day 7 and 8 weeks.
Adherence
Participants will be contacted everyday up to from day 3 
to day 7, to remind them of injection up to day 5 and 
of diary entry up to day 7 (except over the weekend). 
Syringe holders will be accounted for and the number 
of syringes returned in the sharps box will be counted 
through the lid (not strictly) at day 7 before permanently 
locked by the trial team for disposal.
concomitant care
Rescue medications
Participants can take analgesia listed in the protocol as 
non-investigational medicinal product (co-dydramol, 
codeine phosphate, tramadol and paracetamol) for relief 
as required, usage will be recorded. If participants get 
another flare during treatment, this will be recorded 
and a coarse of oral prednisolone 35 mg orally daily for 
5 days will be used for rescue treatment. Low-dose colchi-
cine 500 µg orally twice daily could be used in addition. 
Use of other immune-modifying treatment or NSAIDS is 
prohibited.
outcomes
This is a feasibility study. It is not powered to look for 
inference. Study processes will be analysed. Recruit-
ment and retention rates and willingness of patients to 
be randomised will be calculated. The proportion of 
patients who did not meet eligibility criteria will be exam-
ined. Adherence and compliance rates and qualitative 
feedback will be examined. Economic data on health-
care resource use and health-related quality of life will 
be collected. Safety outcome measures will be reported 
as mandated in a clinical trial of an investigational medic-
inal product protocol.
Primary endpoint/outcome
Feasibility of undertaking a definitive multicentre, 
double-blind, double dummy RCT to obtain clear guid-
ance on the safe management of acute gout attacks in 
patients with chronic kidney disease.
Information from proposed outcome measures for the 
larger study will be sought. Proposed primary outcome 
measures of effectiveness consist of resolution of pain 
that is, time to 50% reduction and complete resolution 
of pain in self-assessed pain intensity in the joint most 
affected at baseline measure on the Visual Analogue 
Scale (0–100 mm) and 5-point Likert scale from baseline 
to 7 days’ postrandomisation (day 1, day 2, day 3, day 4, 
day 5, day 6, day 7) using composite time points kept to 
24 hours intervals as close as possible.
Proposed secondary outcome measures will consist of 
patient reported outcome measure (day 1, day 2, day 3, 
day 4, day 5, day 6 and day 7), physician assessment of 
joint tenderness and swelling (day 1, day 2 and day 7), 
assessment of activity limitation and quality of life: Health 
Assessment Questionnaire Disability Index and 36-Item 
Short Form Survey at day 1, day 7 and 8 weeks; Five-level 
EuroQol Five-Dimensional Questionnaire at day 1, day 2, 
day 7 and 8 weeks; Lower Extremity Functional Scale at 
day 1, day 2, day 7. Time to take rescue medication and a 
limited assessment of healthcare resource will be made.
Blood and urine tests renal on day 1, day 2, day 7 and 
8 weeks, consisting of full blood count, urea and electro-
lytes, estimated GFR glucose, C reactive protein, serum 
uric acid and spot urine uric acid.
Participant timeline
sample size
This is a feasibility study and we will aim to recruit at least 
16 patients in each arm of the study. The sample size was 
obtained from a recommendation based on the feasibility 
of running a parallel group design. The study will aim to 
enrol for 15 months.
recruitment
Recruitment will be from secondary care, either when 
potential participants present with acute gout attack or 
if in-patients develop acute gout attack. Trial centres will 
be encouraged to work with primary care centres to iden-
tify potential participants and give letter of invitation. 
We will use ethically approved advertising material in the 
community. Potential participants will be given or sent a 
participant information sheet (see online supplementary 
material).
Our hospital serves a population of 350 000 and had an 
average of 47 patients per year over the last 4 years with 
approximately 50% of patients having chronic kidney 
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disease (ie, 23 patients per year). Enrolment is for 15 
months from six centres, we will only recruit patients in 
working hours, that is, 9:00–17:00, it would be logisti-
cally difficult to avoid delays to treatment if participants 
present out of hours and face-to-face assessments cannot 
be done at weekends due to lack of research infrastruc-
ture in most small to medium-sized hospitals. All hospi-
tals should be able to have pharmacy support to provide 
preparation and recording of treatment administered.
Potential participants would hopefully be fully aware 
of study if a letter of invitation was already sent to them. 
Otherwise, potential participants can have up to 24 hours 
to decide if they wish to take part in the study. Analgesia 
that is listed can be used if required; however, baseline 
assessments can only occur 4 hours after administration 
of last dose, that is, before the administration of the next 
dose. Treatment cannot be withheld during this period 
and exclusion criteria will be applied if duration of attack 
is longer than accepted or if contraindicatory medication 
is administered.
Allocation
Sequence generation
Enrolled patients will undergo 1:1 randomisation in 
blocks of four. Randomisation will be undertaken using 
an internet-based randomisation system within Anglia 
Ruskin Clinical Trial Unit (ARCTU). The ARCTU uses 
the Trans European Network Alea (TENALEA) system 
provided by the Trans European Network for Clinical 
Trial Service.
concealment mechanism
Once a patient has consented to take part in the trial, the 
designated staff will log in to the TENALEA web page to 
confirm eligibility and a random allocation will be sent 
to pharmacy. All investigators involved with the trial will 
be blinded to treatment. Patients will not be informed of 
their assigned treatment during the study. Pharmacy will 
keep a record of allocated treatment arms in the event 
emergency unblinding is required.
Implementation
Anakinra and its placebo will be supplied by the manufac-
turer. Intramuscular methylprednisolone and its placebo 
(Lipofundin) will be prepared by a research team member 
not involved with the study.
Study labels will be provided to preserve blinding. 
Anakinra and its equivalent placebo will be provided by 
the manufacturer, once allocation is known, pharmacy 
will use label stating ‘Anakinra or placebo’ using standard 
operating procedure. Five individual syringes labelled 1 
to 5 will be placed individual transparent syringe holders 
and packed for dispensing with a local pharmacy label. 
For intramuscular methylprednisolone (Depo-Medrone) 
and Lipofundin, a member of the study team not involved 
with the trial will draw the treatment and label with a study 
label stating ‘Depomedrone or placebo,’ using a standard 
operating procedure.
blinding
All trial investigators will be blinded to the intervention. 
Pharmacy will keep a record of treatments administrated. 
All trial participants, care providers and outcome asses-
sors will be blinded to the treatment. Each treatment has 
its equivalent placebo to ensure blinding in maintained 
throughout study.
Emergency unblinding
The treatment code for a participant can be broken by 
any clinician either directly or via contact of the prin-
cipal investigator, allocation lists are available to the 
site pharmacy will provide 24-hour cover. Failing that, 
the central pharmacy can access allocation list. Where 
possible the local investigator should aim to discuss the 
need for unblinding with the coordinating investigator 
and blind should be endeavoured to be preserved to rele-
vant research staff (data collection, analysis and interpre-
tation). The coordinating investigator is responsible for 
pharmacovigilance management and reporting.
MEthods: dAtA collEctIon, MAnAgEMEnt, AnAlysIs
Data collection methods
Data collection will be by electronic clinical research 
forms (eCRF), these can be printed out if required for 
convenience of data collection (and act as source docu-
ment) and then data inputted onto eCRF. Data can also 
be inputted direct onto eCRF and the completed eCRF 
can be printed out to act as source documents.
training plans
Study investigators must be aware of the classification 
criteria for gout. For the purposes of this study, each prin-
cipal investigator will be asked to go through a presenta-
tion that will be available online and asked to attend study 
days where concerns will be raised.
Quality control of data and results
Entered data will continuously reviewed by the data 
manager and any gaps in data will be fed back to the 
centre trial team. Routine blood results will be taken 
from the National Health Service (NHS) system. Samples 
for additional testing will be transported as per standard 
operating protocol to the co-ordinating centre.
Participant retention and withdrawal
Enrolled participants will be contacted daily (weekdays) 
by the study team for a week. Participants may withdraw 
from the study for any reason at any time. The investi-
gator may also withdraw participants from the study to 
protect their safety and/or if they are unwilling or unable 
to comply with required study procedures after discussion 
with the chief investigator. Participants who ask to stop 
study treatment, become pregnant or develop a serious 
infection (necessitating intravenous antibiotic treatment 
and hospital admission) should continue to attend all 
follow-up study. Participants who withdraw their consent 
at any point will be asked of their wish regarding the use 
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of data collected up to the point of withdrawal. Partici-
pants who do not attend follow-up assessment after site 
staff have attempted to contact the patient at least twice, 
for example, by telephone may be considered for with-
drawal, the data already collected for them may be used 
and therefore needs returning in the usual manner. The 
PI responsible for a patient may choose to withdraw a 
patient from a trial for appropriate medical reasons, be 
they individual adverse events or new information gained 
about a treatment.
data management
Information from the patient diary and functional assess-
ments will be entered onto an eCRF. Data will be entered 
as it is possible to do so that is, day 1, day 2, day 7 and 
2 months. Referential data rules, valid values and range 
checks will be support by the data entry software. The 
data manager will review the data being sent at regular 
intervals and report back to the centre if there is any 
discrepancy. All forms, hard drives and storage devices 
related to the study will be kept in locked cabinets. Access 
to the study data will be restricted; a password system will 
be used to control access. Data will be stored at MACRO 
database.
study status reports
Regular updates of the study will be sent to the principle 
investigators via email and will be posted on the study 
website.
statistical methods
The sample size will be too small for estimates to have 
adequate precision, and some methods will not be techni-
cally possible for some patterns of missing values. To make 
use of data obtained, comparison of groups with the use 
of time-to-event (‘survival’) analysis will be undertaken 
where relevant. Comparison of continuous outcome 
measures will be undertaken with repeated measures 
analysis of variance with permutation tests. Two-sample 
comparisons of means will be by the two-sample permu-
tation test. The association between the intervention and 
categorical variables will be tested using Fisher’s exact 
test.
Economic analysis
Economic evaluation
Formal economic evaluation looking at the incremental 
cost-effectiveness of anakinra compared with the compar-
ator is not planned as this is a feasibility study. We will 
collect relevant data on resource use (costs) and health-re-
lated quality of life to inform subsequent large-scale study. 
Key drivers of costs, resource allocation and scalability will 
be determined.
Qualitative analysis
Twelve participants who give their specific informed 
consent for participation in the qualitative study will 
selected for an interview around their last 8 week follow-up. 
The interview will cover areas such as how participants 
became involved with the trial, the information that was 
provided for them, the process of obtaining informed 
consent and any areas that felt was not adequately covered 
or could have been undertaken differently.
data monitoring
The Trial Steering Committee will consist of the chief 
investigator (CI), trial coordinator, funding coapplicants 
and two members of patient group will bring indepen-
dent representation. The TSC will take on some aspects 
of pharmacovigilance. There will be no data monitoring 
committee as this is a small feasibility study with a short 
duration and short follow-up, and pharmacovigilance is 
a component of the study. The Trial Management Group 
(TMG) will consist of the CI, funding coapplicants, 
representative of the clinical trials units including trial 
coordinator, data manager and statistician. They should 
meet every 2 months to ensure all practical details of the 
trial are progressing well and adequate targets are met. 
The patient group consists of patients (and family) from 
Southend University hospital with chronic kidney disease 
and suffer from acute gout attacks.
Interim analysis
There will be no interim analysis as this is a feasibility 
study, the study procedures will be regularly reviewed at 
the trial steering committee.
harms
Reporting of adverse events will start at the point of 
consent and reporting for adverse reaction starts at first 
IMP dose until 7 days’ post-treatment. At each contact 
with the subject during the treatment period, the inves-
tigator must seek information on adverse events by 
specific questioning and, as appropriate, by examination. 
All clearly related signs, symptoms and abnormal diag-
nostic procedures should be recorded using the National 
Cancer Institute (NCI) common terminology criteria for 
adverse events (CTCAE) V.4.0 event terms and grading. 
The clinical course of each event should be followed until 
resolution or stabilisation.
Reporting will follow local operating procedure and 
study protocol with oversight from the coordinating 
centre. Non-serious adverse events or reactions will be 
recorded in the study file with follow-up; and reported 
for review by the coordinating investigator within a 
month. All SAEs*/ suspected unexpected serious adverse 
reaction (SUSARs) must be recorded on the SAE form/
adverse event clinical research form (AECRF) form and 
faxed to the sponsor within 24 hours of the research staff 
becoming aware of the event. Any change of condition 
or other follow-up information should be faxed to the 
sponsor as soon as it is available or at least within 24 hours 
of the information becoming available. Events will be 
followed up until the event has resolved or a final outcome 
has been reached. All SAEs assigned by the PI or coordi-
nating investigator as both suspected to be related to IMP 
treatment and unexpected will be classified as SUSARs 
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and will be subject to expedited reporting to the Research 
Ethics Committee and Medicines and Healthcare Prod-
ucts Regulatory Agency (MHRA). The CI will complete 
the Council for International Organisations of Medical 
Sciences form and if warranted, an investigator alert may 
be issued, to inform all investigators involved in any study 
with the same drug (or therapy) that this serious adverse 
event has been reported.
Potential events/reactions reported with anakinra 
consist of neutropaenia, infection and less serious ones 
consist of injection site reactions such as erythema, 
pruritus and rash. Potential events/reactions with steroid 
treatment consist of worsening hypertension, blood sugar 
reading/uncontrolled diabetes and clinical signs of fluid 
retention. Pre-existing conditions should not be reported 
as AE unless the condition worsens by at least CTCAE 
grade during trial. The condition must be reported in 
the pretreatment section of the eCRF, if symptomatic at 
the time of entry or under concurrent medical conditions 
if asymptomatic. Given the potential of clinical events 
related to underlying comorbid disease burden of poten-
tial participants, events that are recognised and expected 
complications of the condition are exempt from normal 
reporting procedure, unless they are of an unexpected 
severity. Common expected events in these patients may 
consist of worsening complications of chronic kidney 
disease, heart failure, hypertension, diabetes complica-
tions, underlying cardiac disease with complications such 
as ACS, arrhythmia, hypotension, tachycardia and wors-
ening oedema. Other exceptions to (serious) adverse 
events SAEs or serious adverse reactions (SARs) reporting 
consist of routine treatment or monitoring of the studied 
indication not associated with any deterioration in condi-
tion, associated with any deterioration in condition, for 
example, preplanned hip replacement operation which 
does not lead to further complications, any admission to 
hospital or other institution for general care where there 
was no deterioration in condition, treatment on an emer-
gency, outpatient basis for an event not fulfilling any of 
the definitions of serious as given above and not resulting 
in hospital admission, any death or hospitalisation due to 
fall or fracture, any death or hospitalisation due to exac-
erbation of an existing medical comorbid condition.
Auditing
The study will be subject to monitoring, inspection and 
audit by Anglia Ruskin Clinical Trials Unit, Southend 
University Hospital NHS Foundation Trust acting as the 
Sponsor and other regulatory bodies to ensure adher-
ence to Good Clinical Practice (GCP).
EthIcs And dIssEMInAtIon
The study will be conducted in accordance with the prin-
ciples of GCP. A favourable ethical opinion was obtained 
from the London-Central Research Ethics Committee, 
reference number 15/LO/1922. Results will be published 
in peer-reviewed journal and disseminated at interna-
tional conferences.
Protocol amendments
Protocol amendments to the protocol or study documents 
will be submitted to the REC and can only be imple-
mented once approval has been obtained. Amendments 
to the clinical trials authority (CTA) or documents that 
supported the original CTA application will be notified to 
the MHRA. Amendments will be tracked in the protocol 
appendix and the version of the protocol will be updated.
consent
A clinician in the research team will obtain informed 
consent from potentially eligible participants. Patients 
who are unable to consent for themselves for suitability 
for the trial will not be approached as obtaining patient 
reported outcome measures will not be practical. If verbal 
translation is needed, this should be via a hospital inter-
preter or a personal interpreter. Telephone interpreta-
tion services are not acceptable and written material will 
not be provided in various languages for this feasibility 
study. This study utilises questionnaire surveys that have 
not been validated in different languages. There is also 
a qualitative element to the study where lack of required 
language skill may prove to be difficult. Time is limited 
for potential participants to be considering participation 
and any delays in seeking consent and translation services 
that may prolong treatment of the patient in acute pain 
have also to be considered.
Written material consisting of participant information 
leaflet and consent documentation (see online supple-
mentary material) that has been approved by the Research 
Ethics Committee and will be compliant with GCP, local 
regulatory and legal requirement. This is a feasibility 
study and the costs to undertake centrally commissioned 
translated documents may be too high. This may be some-
thing to consider for the subsequent definitive study.
There will be opportunity for the participant to ask 
questions to the PI or a member of the research team. 
Potential participants can have up to 24 hours to consider 
the information and their participation. However, treat-
ment cannot be withheld during this period and exclu-
sion criteria will be applied if duration of attack is longer 
than accepted or if contraindicatory medication is 
administered.
Ancillary studies
There will be a tertiary/exploratory study where patient’s 
serum and urine will be stored for future analysis at the 
end of the study. Testing will be an extension of routine 
laboratory testing to look for markers of inflammation in 
an exploratory setting.
confidentiality
All investigators and trial site staff must comply with 
the requirements of the Data Protection Act 1998 with 
regards to the collection, storage, processing and disclo-
sure of personal information and will uphold the Act’s 
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core principles. Information with regards to study patients 
will be kept confidential and managed in accordance with 
the Data Protection Act, NHS Caldicott Guardian, The 
Research Governance Framework for Health and Social 
Care and Research Ethics Committee Approval.
Data will be stored for 5 years before being destroyed. 
The chief investigator in the data custodian.
declaration of interest
The coordinating investigator has not obtained any 
personal grants, a investigator sponsored study grant 
of £10 000 and provision of Anakinra and its equivalent 
placebo is being provided for the study by the manufac-
turer’s. This fund will be used to cover any predominantly 
pharmacy and logistics costs.
Access to data
Only the data manager will have access to data and coor-
dinate access to relevant researchers. The health econ-
omist will have access to health economic data set and 
qualitative researcher will have access of patient demo-
graphics to obtain a broad sample.
Ancillary and post-trial care
Acute gout attack episodes will be treated as part of this 
trial. If participants get another acute attack of gout, they 
will not be eligible to entry into the study. The partici-
pating team could consider using information with 
regards to treatment to avoid and available treatment 
options, but no information will be made available prior 
to the end of the trial.
dissemination policy: trial results and authorship
The trial report will be used for publications and presen-
tation at scientific meetings. All publications and presen-
tations will be reviewed by the TMG. Authorship will 
be determined per internationally agreed criteria for 
authorship. Funding bodies will be declared in publica-
tions. The full report will be made available directly from 
the chief investigator or from published material. Supple-
mental material linked with publication will consist of the 
trial protocol.
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